Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04083599 · ClinicalTrials.gov registry record · Phase 1
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
A Phase 1 study of Melanoma and Non-small Cell Lung Cancer (NSCLC), sponsored by Genmab.
- Active
- Registry status
- Phase 1
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT04083599 is a Phase 1 study of Melanoma and Non-small Cell Lung Cancer (NSCLC) that is active but no longer recruiting, run by Genmab. The registered enrollment target is 350 participants, below the 705-participant average among 266 other Melanoma trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT04083599, a Phase 1 study of Melanoma and Non-small Cell Lung Cancer (NSCLC), is active but no longer recruiting, sponsored by Genmab.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this trial is to learn about the antibody GEN1042 when it is used alone and when it is used together with another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of participants with certain types of cancer.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG 5-FU
- BIOLOGICAL GEN1042
Study Locations (20)
California
- Cancer & Blood Specialty Clinic - Los Alamitos
- Moores Cancer Center at the UC San Diego Health - San Diego
Florida
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Florida Cancer Affiliates - Ocala
Kentucky
- University of Kentucky - Lexington
- Norton Cancer Institute - Louisville
North Carolina
- Levine Cancer Center - Charlotte
- Novant Health Cancer Institute - Forsyth (Medical Oncology) - Winston-Salem
Pennsylvania
- University of Pennsylvania - Philadelphia
- Fox Chase Cancer Center - Philadelphia
Alaska
- Alaska Oncology and Hematology LLC - Anchorage
Connecticut
- Yale University Cancer Center - New Haven
Delaware
- ChristianaCare - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2019-09-17 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04083599
The ClinicalTrials.gov registry entry for NCT04083599 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 705-participant average among 266 other Melanoma trials with a reported enrollment target (50% lower). The listed sponsor is Genmab, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Melanoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT04083599 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT04083599 about?
NCT04083599 is a clinical study titled "GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors". The goal of this trial is to learn about the antibody GEN1042 when it is used alone and when it is used together with another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of participants with certain types of cancer.
What is the current status of trial NCT04083599?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 350 participants. The study started on 2019-09-17. Estimated completion is 2026-11.
What conditions does trial NCT04083599 study?
This clinical trial studies the following conditions: Melanoma, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Head and Neck Squamous Cell Carcinoma (HNSCC).
What interventions are being tested in trial NCT04083599?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), 5-FU (DRUG), GEN1042 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04083599?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04083599 being conducted?
This trial has 20 study locations across Alaska, California, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.